Collaboratories
The Nebraska Nanomedicine Production Plant is actively collaborating with academic and pharmaceutical industry programs. Currently, plant projects are ongoing with Exavir Therapeutics and ProTransit Nanotherapy.
Exavir Therapeutics
Drs. Howard Gendelman, Benson Edagwa and Mr. Alborz Yazdi are the cofounders of Exavir Therapeutics. This startup company was founded with the mission of putting an end to HIV. These three founders have a vastknowledge of HIV and other chronic disorders that spans many years along with multiple disciplines fromacademic research to biopharmaceutical industrial experience. The company is focused on Ultra-Long-Acting Therapeutics, targeting HIV integrase and a CRISPR-based cure for HIV. These methods are producing products that will be scaled up to be used in clinical trials.
The Nebraska Nanomedicine Production Plant provides vital product validation to Exavir Therapeutics. Exavir will uses plant equipment and resources necessary for large-scale nanoparticle production, accelerating production and testing for these pending clinical trials.
Learn more about Exavir Therapeutics
ProTransit Nanotherapy
Gary Madsen, MD is the President and CEO of ProTransit Nanotherapy. This start up company, founded in April 2013, focuses on developing nanoparticles with broad applications. The company is working on a range of therapeutics for spinal cord injuries, strokes and traumatic brain injuries as well as for skincare and cosmetics. It is preparing to scale up nontoxic and biodegradable nanoparticles containing active antioxidant enzymes that eliminate damaging free radicals.
With that goal in mind, the Nebraska Nanomedicine Production Plant provides vital product validation to ProTransit Nanotherapy. ProTransit Nanotherapy uses plant equipment and resources necessary for large-scale nanoparticle production, accelerating production and testing for pending clinical trials.
With GMP production capabilities for nanoformulations, the plant is able to provide board resources to local and national pharmaceutical companies with interest in nanoformulations. Dr. Madsen expects other pharmaceutical companies will contact the plant and use its unique set of resources.